Online inquiry

IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6234MR)

This product GTTS-WQ6234MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets RABVgp4 gene. The antibody can be applied in Rabies research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NP_056796.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1489856
UniProt ID P08667
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6234MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ215MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 13C5.5
GTTS-WQ3385MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AT-005
GTTS-WQ4391MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-224818
GTTS-WQ758MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AB0024
GTTS-WQ10205MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LDP-02
GTTS-WQ2345MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AME-133v
GTTS-WQ13649MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ8749MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IBI-101
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW